Menu
Back to Journals » Clinical Ophthalmology » Volume 13
Monitoring and management of the patient with pseudoexfoliation syndrome: current perspectives
Authors Tekin K, Inanc M, Elgin U
Received 22 November 2018
Accepted for publication 8 February 2019
Published 1 March 2019 Volume 2019:13 Pages 453—464
DOI https://doi.org/10.2147/OPTH.S181444
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 2
Editor who approved publication: Dr Scott Fraser
Kemal Tekin,1 Merve Inanc,1 Ufuk Elgin2
1Ophthalmology Department, Erciş State Hospital, Erciş, Van, Turkey; 2Ophthalmology Department, Ulucanlar Eye Training and Research Hospital, University of Health Sciences, Ankara, Turkey
Abstract: Pseudoexfoliation syndrome (PES) is a complex and age-related systemic disorder characterized by the progressive accumulation and granular deposition of pseudoexfoliative material in various intraocular and extraocular tissues. The diagnosis of PES is so important because it is a major risk factor for complications during cataract surgery and the most frequent cause of secondary glaucoma. In addition to ocular complications, PES is related with numerous systemic abnormalities, for which the list is growing steadily. Therefore, management and monitoring of patients with PES are crucial. The aim of this paper was to review current perspectives on monitoring patients with PES and addressing management of ocular and systemic associations of this clinically important and biologically fascinating disease.
Keywords: management, monitoring, pseudoexfoliation syndrome, cataract, pseudoexfoliation glaucoma
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.